Breaking News Alert! Exciting news for multiple myeloma patients! A groundbreaking CAR-T therapy has been approved for launch in China!
π Breaking News Alert! π
π Exciting news for multiple myeloma patients! A groundbreaking CAR-T therapy has been approved for launch in China! π
multiple myeloma
CARsgen
πOn March 1st, 2024, CARsgen, a leading Chinese pharmaceutical company, proudly announced the official approval by the National Medical Products Administration (NMPA) of their innovative CAR-T cell immunotherapy product, Zevor-cel, targeting BCMA. This revolutionary treatment is specifically designed for adult patients with relapsed or refractory multiple myeloma who have undergone at least three prior lines of treatment, including a proteasome inhibitor and an immunomodulatory agent.
Β
Zevor-cel
π Zevor-cel marks CARsgen’s debut commercial product, promising a new ray of hope for patients. While the price remains undisclosed, anticipation is high as it is expected to be competitive with its counterparts. Stay tuned as we eagerly await the reveal of its pricing strategy!
Β
πͺAt the 2023 ASH Annual Meeting, Zevor-cel’s impressive three-year follow-up data stole the spotlight, boasting a remarkable Overall Response Rate (ORR) of 100% and a median Progression-Free Survival (PFS) of 25.0 months. With a median Overall Survival (OS) yet to be reached, the two-year OS rate has already hit 100%, and the three-year OS rate stands at a remarkable 92.9%, underscoring its outstanding safety profile and offering renewed hope for patients battling relapsed or refractory multiple myeloma.
Β
Multiple Myeloma
πIn terms of approved indications, it’s worth noting that the current portfolio of domestic CAR-T therapies in China caters to various hematologic malignancies. While FOSUNKITE and JW Therapeutics target lymphomas, JUVENTAS focuses on leukemia. CARsgen and IASO Bio, however, have set their sights on multiple myeloma, aligning perfectly with the pressing medical needs of patients in this category.
Β
πLet’s celebrate this remarkable milestone in the fight against multiple myeloma, as we continue to strive for better, more effective treatments to improve patients’ lives worldwide! π #TogetherWeCanBeatCancer
Β
If you are interested in the latest cancer-fighting technologies and treatment methods in China, or if any of patients wish to learn more, our team is available to support and advise you and your patients at any time.
WebsiteοΌ[https://www.medtourcn.com/]
WhatsappοΌ+8613717959070
Email: doctor.huang@globecancer.com
Β
π #Zevorcel #CARsgen #MultipleMyeloma #CARTTherapy #MedicalBreakthrough #NMPAApproval #HopeForPatients #HealthcareInnovation #CancerTreatment #MedicalAdvancement